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Introduction: Since the concept of reprogramming mature somatic cells to generate induced pluripotent stem
cells (iPSCs) was demonstrated in 2006, iPSCs have become a potential substitute for embryonic stem cells (ESCs)
given their pluripotency and “stemness” characteristics, which resemble those of ESCs. We investigated to
reprogram fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) to
generate iPSCs using a 4-in-1 lentiviral vector system.
Methods: A 4-in-1 lentiviral vector containing Oct4, Sox2, Klf4, and c-Myc was transduced into RA and OA FLSs
isolated from the synovia of two RA patients and two OA patients. Immunohistochemical staining and real-time
PCR studies were performed to demonstrate the pluripotency of iPSCs. Chromosomal abnormalities were determined
based on the karyotype. SCID-beige mice were injected with iPSCs and sacrificed to test for teratoma formation.
Results: After 14 days of transduction using the 4-in-1 lentiviral vector, RA FLSs and OA FLSs were transformed into
spherical shapes that resembled embryonic stem cell colonies. Colonies were picked and cultivated on matrigel plates
to produce iPSC lines. Real-time PCR of RA and OA iPSCs detected positive markers of pluripotency. Immunohistochemical
staining tests with Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 were also positive. Teratomas that comprised three
compartments of ectoderm, mesoderm, and endoderm were formed at the injection sites of iPSCs. Established iPSCs were
shown to be compatible by karyotyping. Finally, we confirmed that the patient-derived iPSCs were able to differentiate
into osteoblast, which was shown by an osteoimage mineralization assay.
Conclusion: FLSs derived from RA and OA could be cell resources for iPSC reprogramming. Disease- and patient-specific
iPSCs have the potential to be applied in clinical settings as source materials for molecular diagnosis and regenerative
therapy.Introduction
The concept of reprogramming mature somatic cells to
generate induced pluripotent stem cells (iPSCs) was dem-
onstrated by Takahashi and Yamanaka in 2006 [1]. Four
factors, namely Oct4, Klf4, Sox2, and c-Myc, were trans-
duced into somatic cells to reprogram and generate iPSCs.* Correspondence: juji@catholic.ac.kr
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reproduction in any medium, provided the orSubsequently, iPSCs have become a potential substitute
for embryonic stem cells (ESCs) given their pluripotency
and stemness characteristics, which resemble those of
ESCs [2,3]. iPSCs may have important potential clinical
applications as drug screening platforms, in pathophysio-
logical studies in dishes, and as candidate cell sources for
regenerative medicine [4-7].
The iPSCs used in pathophysiological studies in dishes
were generated from the primary cells that originated from
patients with neurological, hematological, metabolic, car-
diovascular, primary immunodeficiency diseases, and so
on [5,8-10]. These pioneering studies have detected many
novel pathophysiological mechanisms, which were impos-
sible to study previously because of the inaccessibility of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ticularly useful for studying diseases with complex me-
chanisms, which are affected by several factors that
range from the genetic background to environmental
modifications.
Rheumatoid arthritis (RA) may be a promising target
disease for iPSC applications because of its complex
pathophysiology. The iPSCs from RA patients could be
extended to a regenerative approach via their differenti-
ation into mature chondrocytes and osteocytes, which
synthesize cartilage and bone. We therefore selected
fibroblast-like synoviocytes (FLSs) from RA and osteo-
arthritis (OA) for reprogramming using a four-in-one
lentiviral vector, which contained four factors: Oct4,
Klf4, Sox2, and c-Myc. RA FLSs, which are regarded as
major pathophysiological players in RA, are thought to
be a good candidate for reprogramming to simulate the
disease RA in dishes [11-13].
In this study, we successfully reprogrammed RA FLSs
and OA FLSs to generate disease-specific iPSCs. Their
pluripotency was demonstrated by immunohistochemi-
cal staining and teratoma formation in vivo. To our
knowledge, this is the first attempt to induce stem cells
from RA FLSs.
Methods
Patient recruitment and synovia preparation
Four patients were used for synovia preparation. RA pa-
tients (n = 2) who satisfied the 1987 revised criteria of
the American College of Rheumatology (formerly the
American Rheumatism Association) [14] and OA pa-
tients (n = 2) were recruited from the outpatient clinic
at the Department of Rheumatology, Seoul St. Mary’s
Hospital, Seoul, South Korea. These patients had re-
ceived arthroscopic synovectomy or total knee replace-
ment surgery. Synovia samples were obtained during
the operations. Eligibility for OA inclusion required that
individuals had primary knee OA, which was diagnosed
according to American College of Rheumatology cri-
teria. The experimental protocol was approved by the
Catholic University of Korea Human Research Ethics
Committee.
Isolation and maintenance of RA and OA fibroblast-like
synoviocytes
RA and OA synovia were stored in the sample bank of the
Rheumatism Research Center, Seoul, South Korea. These
samples were classified only by disease and stored in a blind
manner. The institutional review board permitted that a
patient consent form was not necessary because samples
were anonymous and did not contain patient information.
Tissues were homogenized and resuspended in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco by Invitrogen,
Carlsbad, CA, USA) containing 0.01% collagenase andwere incubated for 4 hours at 37°C with vigorous shak-
ing. Cells were washed and resuspended in DMEM sup-
plemented with 20% fetal bovine serum (FBS) (Gibco by
Invitrogen), and 1% penicillin/streptomycin solution (Gibco
by Invitrogen). Cells were cultured until the adherent fibro-
blast cells achieved confluence.
Lentivirus production and transduction
293FT cells (Invitrogen, Carlsbad, CA, USA) were plated
at 80% confluence in 100-mm dishes and transfected with
12 μg of four-in-one reprogramming plasmid (Oct4, Sox2,
Klf4, and c-Myc), 9 μg packaging pPAX2 plasmids, and
3 μg pMD2G plasmids using Lipofectamine 2000 (Invitro-
gen). After about 48 to 72 hours of culture, the virus was
harvested and mixed with Lenti-X Concentrator (Clontech
Laboratories, Mountain View, CA, USA). After overnight
incubation at 4°C, viruses were precipitated at 1,500 × g
and resuspended in phosphate-buffered saline. For virus
infection, RA or OA FLSs were seeded onto six-well
plates. The lentivirus was applied with culture medium for
overnight infection. The iPSC colonies were picked after
18 to 20 days of reprogramming.
Cell culture and maintenance of patient-specific iPSCs
RA or OA FLSs were maintained in DMEM containing
20% FBS at 37°C, with 95% air and 5% CO2 in a humidi-
fied incubator. All of the cells used for reprogramming
were at passage 8. Patient-specific iPSCs were maintained
in Matrigel-coated tissue culture dishes (BD Biosciences,
San Jose, CA, USA) with E8 human ESC medium.
Quantitative real-time polymerase chain reaction
Total RNA was isolated using an RNeasy Plus Mini Kit
(Qiagen, Valencia, CA, USA). Reverse transcriptase poly-
merase chain reaction was performed using an iScript™
cDNA Synthesis Kit (BIORAD, Marnes-La-Coquette,
France). Gene expression was quantified by SYBR Green
real-time polymerase chain reaction using an ABI Prism
7300 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). The relative mRNA levels were
normalized to the values of GAPDH mRNA for each re-
action. The primer sequences are described in Additional
file 1.
Immunostaining
The iPSC clones were fixed with 4% paraformaldehyde
and immunostaining was performed using the following
primary antibodies: SSEA-4, Tra-1-60 and Tra-1-80
(Millipore, Billerica, MA, USA), Oct3/4 and Nanog (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and Sox2
(BioLegend, San Diego, CA, USA). Samples were incu-
bated with Alexa Fluor 594-conjugates or 488-conjugated
secondary antibody (Invitrogen) and detected by indirect
immunofluorescence microscopy.
Figure 1 Successful generation of induced pluripotent stem cells from rheumatoid arthritis and osteoarthritis fibroblast-like synoviocytes.
(A) Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) and osteoarthritis (OA) FLSs were cultured before reprogramming. RA and OA FLS was
extracted from RA patients (n = 2) and OA patients (n = 2) and were cultured as previously documented. There were five passages of RA and OA FLSs.
Synovium was gathered from the elbow and knee during synovectomy surgery. One sample (RA1) was from a disease-modifying antirheumatic
drug-naïve patient and the other sample (RA2) from a biologics-refractory patient with persistent high disease activity. (B) Tomato fluorescence was
shown shortly after virus infection. On the 6th day after the transduction of four-in-one viral vector on RA FLSs, colony-like spheres began to form. On
the 18th day, colonies were picked and resuspended on Matrigel-coated culture dishes. (C) Tomato fluorescence was positively shown on four-in-one
vector-transduced OA FLSs. On the 7th day after the transduction of four-in-one viral vector on OA FLS, colony-like spheres began to form. On the
11th day, colonies were picked and resuspended on Matrigel-coated culture dishes.
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Teratoma formation was performed and analyzed with
the approval of the Institutional Animal Care and Use
Committee of Applied StemCell (protocol number APP-
12-001-Y2; Sunnyvale, CA, USA). Briefly, undifferentiated
iPSCs (1 × 106) were suspended in 10 μl Matrigel (BD Bio-
sciences) and delivered using a 28.5 gauge syringe into the
subrenal capsule of 8-week-old SCID-beige mice. Eight
weeks after cell delivery, the tumors were explanted and
subjected to hematoxylin and eosin staining.Osteogenic differentiation
For osteogenic differentiation, we cultured iPSCs in osteo-
genic differentiation medium (ODM) as described by Kao
and colleagues [15]. ODM is DMEM supplemented with
15% FBS, 50 μg/ml ascorbate-2-phosphate, 10 nmol/l dexa-
methasone, and 10 mmol/l β-glycerophosphate. At day 7after osteogenic induction, in vitro mineralization of cells
was assessed using the OsteoImage Mineralization Assay
kit (Lonza, Basel, Switzerland) according to the manufac-
turer’s manual. Fluorescent signals from the hydroxyapa-
tate portion were detected by fluorescence microscope
(Axio observer 2.1; ZEISS, Thornwood, NY 10594, USA).Karyotyping
We added 30 μl Chromosome Resolution Additive (Genial
Genetic Solutions Ltd, Runcorn, UK) to each six-well plate.
After 1 hour of incubation, colcemid® was treated for 30
minutes. Cells were harvested using trypsin and treated by
prewarmed hypotonic solution (KCl). Fixation was then
performed with 1:3 acetic acid:methanol solution and the
slide was prepared for chromosome analysis. The chromo-
some analysis was performed using a trypsin-Giemsa band-
ing technique. At least 20 metaphases were analyzed.
Figure 2 (See legend on next page.)
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Figure 2 Positive expression of pluripotency marker on osteoarthritis and rheumatoid arthritis induced pluripotent stem cells. (A) The
expression of stemness genes in osteoarthritis (OA) induced pluripotent stem cells (iPSCs) and rheumatoid arthritis (RA) iPSCs was analyzed by
quantitative reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Total RNA of fibroblast, OA fibroblast-like synoviocytes (FLSs), RA
FLSs, H7, OA iPSCs and RA iPSCs was isolated and analyzed for endogenous pluripotent genes by RT-PCR analysis. The expression of endogenous
Nanog, Oct4, Sox2 and Rex is upregulated in OA iPSCs and RA iPSCs. OA FLS and RA FLS already expressed Klf4 before reprogramming process
started. (B) Immunofluorescence staining against Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 in RA iPSCs. RA iPSCs expressed a high level
of these markers. (C) Immunofluorescence staining against Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 in OA iPSCs. OA iPSCs were positive
for the pluripotency genes such as Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4.
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Results
Isolation of RA and OA fibroblast-like synoviocytes and
successful generation of disease-specific iPSCs
We cultured FLSs from patients with RA (n = 2) and with
OA (n = 2) (Figure 1A). The four-in-one vector was trans-
duced into RA FLSs and OA FLSs, and they were serially
observed. Colonies were formed and picked manually after
18 to 20 days. They were cultured through five passages
(Figure 1B and 1C).
Positive expression of pluripotency markers by RA and
OA iPSCs
RA and OA iPSCs were immunostained against Nanog,
Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4. These factors
all stained positively in six iPSC clones that originated
from two RA patients and two OA patients (Figure 2B, 2C
and Additional file 2). The pluripotency mRNA markers
for Nanog, Oct4, Sox2, Klf4, and Rex also increased, ac-
cording to the real-time reverse transcriptase polymerase
chain reaction analysis (Figure 2A). Interestingly, the level
of Klf4 was elevated before reprogramming in RA FLSs
and OA FLSs. Other factors began to increase after repro-
gramming and they peaked at higher levels than those
found in H7 cells.
Successful teratoma formation and normal karyotyping
The RA iPSC karyotype had a normal chromosomal
pattern of 44 + XX (Figure 3A). RA iPSCs were injected
into the kidney capsule and testis of SCID mice. At 12
weeks, teratomas formed successfully and they com-
prised three compartments: ectoderm, mesoderm, and
endoderm (Figure 3B). Each compartment contained
glandular tissue, connective tissue, blood vessels, adi-
pose tissue, and skin-like structures.
Osteogenic differentiation of RA and OA iPSCs
To confirm the osteogenic capability of patient-derived
iPSCs, we tried to differentiate RA and OA patient-specific iPSCs to osteocytes. RA iPSCs and OA iPSCs were
incubated in ODM to induce osteogenic differentiation
(Figure 4). After 7 days of osteogenic induction, in vitro
mineralization of cells was assessed by the OsteoImage
Mineralization Assay Kit (Lonza). Fluorescent signals for
mineralization were detected in RA iPSCs and OA iPSCs
incubated with ODM, which means osteogenic cells were
successfully differentiated from these iPSCs. This result
shows that patient-derived iPSCs have a potential for bone
formation.
Discussion
Insights into the pathophysiology of RA have been derived
largely from animal models such as collagen-induced arth-
ritis, collagen antibody-induced arthritis, IL-1RaKO mice,
and KBX/N serum transfer mice. However, the existing
arthritic mouse model is not fully representative of the ac-
tual pathophysiology in patients with RA [16,17]. Indeed,
it has been frequently suggested that insights from mouse
models have rarely translated successfully to the clinic
[18]. The production of simulation platforms and better
access to genetically predisposed human cells may allow
scientists to study the pathophysiology of diseases with
greater ease. Previously, it was impossible to perform
in vitro mechanistic studies and to produce in vivo trans-
plant systems. The biological status obtained in simulation
platforms using patient-derived iPSCs is now considered
more representative of a disease than other systems. We
thus generated human iPSCs from patients with RA (n = 2)
and with OA (n = 2). Moreover, the osteogenic potential of
RA iPSCs and OA iPSCs was shown by producing hy-
droxyapatite after stimulation with osteogenic differenti-
ation. These results mean that patient-derived iPSCs have
a potential of differentiation into tissues like other stem
cells. We are going to investigate that these RA iPSCs and
OA iPSCs could be suitable candidate materials for disease
modeling and drug screening platforms.
The generation of disease-specific iPSCs has been
attempted for many diseases [5,19-23]. The initial target
diseases of iPSC generation were genetic deficiency dis-
eases such as congenital anomalies or familial inherited
diseases. Recently, iPSC studies have been extended to
chronic diseases where the genetic etiology plays a less
significant role than was the case in diseases studied
Figure 3 Characterization of rheumatoid arthritis induced pluripotent stem cells. (A) High-resolution, G-banded karyotype indicated a
normal diploid female chromosomal content 46XX in rheumatoid arthritis (RA) induced pluripotent stem cells (iPSCs). (B) Teratoma formation
occurred after injection of RA iPSCs into immunocompromised mice. Tumors were detected from the sites of injection and harvested after 3
months, and were examined for the presence of cells of three embryonic germ layers. Teratomas contained tissue from all three germ layers,
including the gland (endoderm), blood vessel (mesoderm), adipose tissue (mesoderm), and skin-like structure (ectoderm).
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logical mechanisms with genetic background and envir-
onmental effects. The progression of RA is explained by
a combination of susceptible genetic background and
environmental exposure to Porphyromonas gingivalis,
smoking, and other factors [24,25]. We thus consider that
disease modeling may be applicable to RA after the ge-
neration of disease-specific iPSCs. Various environmental
factors could be used to challenge an RA-simulated plat-
form using iPSCs in a more sophisticated and individual-
specific manner.
RA is characterized by its autoimmune mechanism,
chronic inflammation, cartilage erosion, and bone destruc-
tion. In the final stage, the joints become dysfunctional.The destruction of cartilage and bone are the main causes
of dysfunctionality and many scientists have tried to re-
store the defective areas. However, this approach has met
with little success because of the cell sources used and im-
mune rejection. Patient-specific iPSCs are regarded as
good candidates for regeneration therapy because they
may escape immunological rejection and exhibit pluripo-
tency to differentiate into target cells such as cartilage and
bone [13,26]. However, several issues need to be overcome
before in vivo applications. Every material that is applied
to humans needs to satisfy the rules of good clinical prac-
tice. In particular, good clinical practice guidelines prohibit
the use of animal-derived products and oncogenic mater-
ial, which is why the clinical application of iPSCs will
Figure 4 In vitro osteogenic differentiation of rheumatoid
arthritis and osteoarthritis induced pluripotent stem cells.
To induce osteogenic differentiation, rheumatoid arthritis (RA) and
osteoarthritis (OA) induced pluripotent stem cells (iPSCs) were
cultured in E8 medium or osteogenic differentiation medium
(ODM) for 7 days. Osteogenic differentiation was determined by the
fluorescence detection for mineralization. Osteogenic mineralization
was detected in both ODM-treated RA iPSCs (A) and OA iPSCs
(B) by fluorescence microscope (fluorescein isothiocyanate (FITC)).
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velop iPSCs using FBS-free media, feeder-free cultivation,
and integration-free reprogramming, and numerous modi-
fications are required to the protocol used for differenti-
ation from iPSCs [27].
Two of the Yamanaka factors, c-myc and klf4, are
regarded as oncogenes. Several modifications have been
attempted to minimize the expression of these genes such
as changing c-myc to n-myc and other combinations of
factors. Interestingly, some somatic cells already expressed
Klf4 and c-Myc, and therefore only required Sox2 and
Oct4 for reprogramming [28]. In our experiments, RA
and OA FLSs expressed Klf4 at a level that was suitable
for establishing H7 stem cells. We thus expect that RA
FLSs could be reprogrammed into iPSCs using minimized
conditions, which would facilitate the minimal usage of
oncogenes such as c-myc and klf4.
Occasionally, disease-specific iPSCs exhibit altered bio-
logical functions compared with ESCs, such as delayed cell
proliferation and poor differentiation quality [2,3,29]. These
phenomena were attributed to genuine problems with the
primary cells that were reprogrammed. The disease state
and drugs may thus affect the condition of primary cells.
Our iPSCs had the full characteristics of stem cells accord-
ing to immunostaining, karyotyping, and teratoma assays,but they exhibited slight alterations in their biological be-
havior. As various cytotoxic drugs such as methotrexate
and other immunosuppressants are used in RA treatment,
there is a significant possibility of prolonged exposure to
cytotoxic drugs by RA FLSs, which could affect the repro-
gramming process. Further studies are needed to clarify
the relationship between the quality of iPSCs and the pri-
mary somatic cells subjected to reprogramming.
Conclusions
FLSs derived from RA and OA could be cell resources for
iPSC reprogramming. Disease-specific and patient-specific
iPSCs have the potential to be applied in clinical settings
as source materials for molecular diagnosis and regenera-
tive therapy. A molecular diagnostic approach, by disease
in a dish using patient-specific iPSCs, may reveal compli-
cated and individualized pathophysiology of RA. Regener-
ated tissue from patients’ own iPSCs will be a good
material for tissue repair and structural restoration.
Additional files
Additional file 1: Is a table presenting the primer sequences used
in the polymerase chain reaction.
Additional file 2: Is a figure showing positive expression of
pluripotency markers on OA and RA iPSCs. Other clones were
generated during the reprogramming process. Immunofluorescence
staining against Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 in RA
and OA iPSCs. RA and OA iPSCs expressed high level of these markers.
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